Stockreport

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

BAYER AG S/ADR  (BAYRY) 
NASDAQ:AMEX Investor Relations: investor.bayer.com
PDF Bayer revealed first results of the pediatric study from the pivotal clinical development program QUANTI for its low-dose MRI contrast agentQUANTI Pediatric evaluated th [Read more]